Aytu Biopharma (AYTU) Accumulated Expenses (2012 - 2026)

Aytu Biopharma (AYTU) has reported Accumulated Expenses for 15 consecutive years, with $2.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Accumulated Expenses fell 93.43% year-over-year to $2.7 million; the TTM figure through Mar 2026 stood at $2.7 million (down 93.43% YoY), while the FY2025 annual figure was $38.2 million, changed 0.06% from the prior year.
• Accumulated Expenses fell to $2.7 million in Q1 2026 per AYTU's latest filing, from $40.2 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $46.8 million in Q2 2023 and bottomed at $2.7 million in Q1 2026.
• Historically, Accumulated Expenses has averaged $25.1 million across 5 years, with a median of $33.7 million in 2024.
• Annual changes were most pronounced in 2024 — Accumulated Expenses surged 1071.09% — and 2026, when it tumbled 93.43%.
• Aytu Biopharma's Accumulated Expenses stood at $41.2 million in 2022, then plunged by 91.84% to $3.4 million in 2023, then soared by 1071.09% to $39.4 million in 2024, then increased by 1.99% to $40.2 million in 2025, then sank by 93.17% to $2.7 million in 2026.
• Business Quant data shows AYTU's Accumulated Expenses at $2.7 million in Q1 2026, $40.2 million in Q4 2025, and $4.0 million in Q3 2025.